Immunotherapy of cancer and perspectives of its development

Mackiewicz, Jacek; Maćkiewicz, Andrzej

doi:10.5114/wo.2010.13914

Cited by 7 publications

(3 citation statements)

References 105 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The melanoma malignum incidence is on the rise practically worldwide and at the same time there are promising modern therapies available, especially immunotherapy [1], including so-called therapeutic cancer vaccines [2]. Unfortunately, the melanoma malignum is difficult to diagnose, as sometimes the primary lesion is untraceable while the metastases are present already [3]; the lesions can also look in many different ways, so the clinical doctors often call it "the great imitator" -sometimes the non-neoplasm changes can raise serious suspicions of melanoma malignum while in fact being of different origin or even iatrogenic artefacts [4].…”

Section: Introductionmentioning

confidence: 99%

Analysis of Statistical Changes in Melanoma Malignum Cases Amount (C43 ICD-10) in Lower Silesia Region of Poland in Years 2006-2012

2016

International Journal of Research Studies in Medical and Health

View full text Add to dashboard Cite

ABSTRACT:Melanoma malignum incidence is on rise practically worldwide. In order to estimate yearly incidence and relevant current trends in Lower Silesia's population, data on registered medical interventions because of melanoma malignum (C43-C43.9 according to ICD-10) in the years 2006-2012 were analysed, which were made available due to courtesy of the public healthcare insurance provider Narodowy Fundusz Zdrowia (NFZ). The study revealed increasing trend in melanoma malignum of skin yearly incidence, which encompassed all ICD-10 subcategories with exception of lip and overlapping malignant melanoma. Total amount of yearly registered cases jumped from 4101 in year 2006 to 5807 in year 2012.

show abstract

Section: Introductionmentioning

confidence: 99%

Analysis of Statistical Changes in Melanoma Malignum Cases Amount (C43 ICD-10) in Lower Silesia Region of Poland in Years 2006-2012

2016

International Journal of Research Studies in Medical and Health

View full text Add to dashboard Cite

show abstract

“…Results from preclinical studies and early clinical trials indicate a high potential for combining immunotherapy with other treatment modalities [40].…”

Section: Combined Treatmentmentioning

confidence: 99%

Immunotherapy in advanced cutaneous melanoma patients

Mackiewicz¹,

Krokowicz²

2013

Self Cite

View full text Add to dashboard Cite

SummaryThe incidence of cancer has been increasing worldwide. Melanoma is known to be one of the most immunogenic malignancies in humans. In recent years innovative and promising therapeutic strategies that modulate the immune response or target various intracellular pathways in melanoma have been developed. Recently new drugs which improved overall survival in phase III regulatory studies namely, ipilimumab (anti-CTLA-4 antibody) and vemurafenib (BRAF inhibitor) have been approved in Europe and the USA, and so has a combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in the USA for the treatment of metastatic melanoma. A number of novel immunotherapy strategies including anti-PD-1, anti-PD-1L or cancer vaccines show a durable high response rate in advanced melanoma patients, however efficacy of these drugs needs to be confirmed in phase III studies. Results from preclinical studies and early clinical trials indicate a high potential for combining immunotherapy with other treatment strategies -currently many new drug combinations are being evaluated in phase I or II in patients with metastatic melanoma.

show abstract

“…In oncology investigations continue on individualized vaccines directed against mutated HSPs that are typical of a given tumor [7]. This method of treatment is defined as an active specific immunotherapy using a non-cellular vaccine [8].…”

mentioning

confidence: 99%

The Role of HSP70 Heat Shock Proteins in the Pathogenesis and Treatment of Inflammatory Bowel Diseases

Samborski¹,

Grzymisławski²

2015

Adv Clin Exp Med

View full text Add to dashboard Cite

Heat shock proteins (HSPs) represent an important element in the body's defense against various damaging factors. The probably also play an important role in the pathogenesis and treatment of several diseases, including autoimmune pathology and neoplasms. Recently, several investigators have focused their attention on the involvement of the HSP70 protein family in the morbid process of inflammatory bowel diseases (IBD). The HSP70 family of is represented by two distinct forms of protein, the HSP72 protein (also known as the HSP70.1 protein), the expression of which is clearly increased in conditions of stress; and the HSP73 (or HSC73) protein, which manifests stable expression. HSP70 proteins are present in the colorectal epithelium. In patients with inflammatory bowel diseases, their expression in significantly increased during the active stage of the disease. In experimental studies, overexpression of HSP70 was found to prevent the development of inflammatory process in the large intestinal mucosa provoked by various damaging factors. In physiological conditions, various mechanisms are considered to be responsible for an increased expression of HSP70. One of them involves lymphocyte activity and the production of cytokines (mainly IL-2). Another suggested mechanism involves the presence of bacteria in the large intestine, including both physiological flora (Lactobacillus GG, Bacteroides fragilis) and pathogenic bacteria (Salmonella, Escherichia coli). HSP70 expression is probably also increased by physical activity. There is also a potential for pharmacological stimulation of HSP70 expression, linked (for example) to geranylgeranylacetone, polaprezinc and mesalazine. Thus, augmentation of HSP70 expression may become a new element in IBD therapy (Adv Clin Exp Med 2015, 24, 3, 525-530).

show abstract

Immunotherapy of cancer and perspectives of its development

Cited by 7 publications

References 105 publications

Analysis of Statistical Changes in Melanoma Malignum Cases Amount (C43 ICD-10) in Lower Silesia Region of Poland in Years 2006-2012

Analysis of Statistical Changes in Melanoma Malignum Cases Amount (C43 ICD-10) in Lower Silesia Region of Poland in Years 2006-2012

Immunotherapy in advanced cutaneous melanoma patients

The Role of HSP70 Heat Shock Proteins in the Pathogenesis and Treatment of Inflammatory Bowel Diseases

Contact Info

Product

Resources

About